The FDA peptide compounding landscape is shifting. For months, the research community has been waiting for RFK Jr.’s February promise to become official policy — as of April 1, 2026, the wait appears to be ending.
For months, the peptide research community has been waiting for RFK Jr.’s February promise to become official policy. As of April 1, 2026, the wait appears to be ending.
The New York Times and STAT News are reporting today that the FDA is actively moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned in 2023 due to what the agency cited as potentially significant safety risks. This is the formal regulatory movement the wellness and research communities have been anticipating since Health Secretary Robert F. Kennedy Jr. announced the expected reclassification on Joe Rogan’s podcast in late February.
The compounds affected include some of the most widely researched peptides in the longevity, recovery, and metabolic health space BPC-157, Ipamorelin, CJC-1295, MOTS-c, TB-500, and others that were placed on the FDA’s Category 2 restricted list in September 2023. That restriction effectively shut down licensed compounding pharmacies from preparing these compounds for patients, driving demand toward unregulated online sources.
Kennedy has been vocal about his personal use of peptides and his belief that the 2023 restrictions were counterproductive. On the Joe Rogan podcast, he stated he had used peptides to heal injuries “with really good effect” and that the restrictions had created the very gray market they were meant to prevent.
The formal regulatory process requires the FDA to move these compounds onto a curated list of bulk drug substances that explicitly authorizes compounding pharmacies to prepare them. Once published, licensed 503A and 503B compounding pharmacies would be able to legally produce these peptides under physician supervision, restoring a regulated, quality-controlled access pathway that hasn’t existed for over two years.
No official Federal Register publication has been confirmed at the time of writing, but today’s reporting from major national outlets signals the regulatory machinery is finally in motion. For researchers and clinicians who have been monitoring this situation, the direction is no longer in question — the timeline is.
For a deeper breakdown of peptide legality and regulatory classification in the United States, see our analysis on peptide legality.
For broader context on peptide regulation, safety frameworks, and research applications, explore our Research Library.
The Wellness World Is Eager for RFK Jr.’s Promised Move on Peptides — NPR, March 31, 2026